Vertex Pharmaceuticals Incorporated
VRTX
$493.84
$1.370.28%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 913.00M | 1.05B | -3.59B | 1.10B | 968.80M |
| Total Depreciation and Amortization | 21.30M | 53.20M | 54.00M | 53.50M | 47.20M |
| Total Amortization of Deferred Charges | 25.20M | -- | -- | -- | 11.80M |
| Total Other Non-Cash Items | 185.30M | 113.70M | 27.40M | 24.20M | 45.70M |
| Change in Net Operating Assets | -560.20M | 157.50M | -241.40M | 129.30M | -838.90M |
| Cash from Operations | 584.60M | 1.37B | -3.75B | 1.31B | 234.60M |
| Capital Expenditure | -92.60M | -67.70M | -69.00M | -68.40M | -58.10M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -729.30M | -280.30M | -394.70M | -2.07B | -828.40M |
| Cash from Investing | -821.90M | -348.00M | -463.70M | -2.14B | -886.50M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.30M | -5.40M | -13.70M | -13.20M | -12.00M |
| Issuance of Common Stock | 34.30M | 8.40M | 55.00M | 16.90M | 46.40M |
| Repurchase of Common Stock | -425.20M | -391.40M | -400.80M | -364.70M | -152.70M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 900.00K | 900.00K | 900.00K | 3.50M | -1.50M |
| Cash from Financing | -391.30M | -387.50M | -358.60M | -357.50M | -119.80M |
| Foreign Exchange rate Adjustments | -47.30M | 22.80M | -2.50M | -15.60M | 27.40M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -675.90M | 657.10M | -4.58B | -1.20B | -744.30M |